Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myeloma
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: High‐dose therapy (HDT) and autologous transplantation prolongs remission duration and survival in multiple myeloma (MM), but relapse still occurs at a median of 2 years post‐HDT. In order to investigate whether the number of residual tumour cells in the bone marrow (BM) after transplantation can predict the duration of response, a quantitative allele‐specific oligonucleotide polymerase chain reaction (qASO‐PCR) assay was used to measure tumour load in BM at 3–6 months post‐HDT in 67 patients. The method of maximally selected log‐rank statistics was used to test for the existence of a cut‐off value in the BM tumour load data set. A cut‐off value with respect to progression‐free survival (PFS) was identified (P = 0·001). The estimated threshold for placing patients into a ‘good’ or ‘bad’ prognostic group was 0·015% (n = 22 and 38 respectively) with a median PFS of 64 months vs. 16. Multivariate analysis showed grouping by PCR result to be an independent prognostic factor for PFS (estimated hazard ratio after shrinkage, 3·91). This study identifies for the first time a threshold of the post‐HDT tumour load with prognostic significance for PFS in MM. Quantitative molecular assessment thus may help to identify those patients who are in need of further treatment early after autologous transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“…is a prognostic parameter in multiple myeloma High-dose therapy (HDT) followed by transplantation of autologous bone marrow (BM) or peripheral blood stem cells (PBSCT) prolongs remission duration and survival (OS) when compared with conventional treatment (Attal et al, 1996; Child et al, 2003).”
BackgroundSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 2×
“The number of HDT cycles was included in our proportional hazards model, as the update of the Intergroupe Français du Myelome (IFM) trial (IFM-95) demonstrated a superior outcome for patients treated by sequential HDT (Attal et al, 2003).”
BackgroundMethod
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationMunshi, N. C., Avet-Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P., Samur, M. K., Georgieva, A., Anderson, K. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 532
Rawstron, A. C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R. A., Bumbea, H., Dalva, K., Fuhler, G., Gratama, J., Hose, D., et al. (2008) · Haematologica · doi:10.3324/haematol.11080 · Cited by 513
Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002827 · Cited by 431
Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425
Metadata
- Authors
- Bakkus, M. H. C., Bouko, Y., Samson, D., Apperley, J. F., Thielemans, K., Camp, B. V., Benner, A., Goldschmidt, H., Moos, M., & Cremer, F. W.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2004-08-04
- Volume
- 126
- Issue
- 5
- Pages
- 665-674
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2039847348
- Cited by
- 81
- References
- 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myeloma. https://app.cochat.ai/papers/10.1111/j.1365-2141.2004.05120.x
- The paper
- Bakkus, M. H. C., Bouko, Y., Samson, D., Apperley, J. F., Thielemans, K., Camp, B. V., Benner, A., Goldschmidt, H., Moos, M., & Cremer, F. W. (2004). Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2004.05120.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.